tesofensine

Tesofensine is a first-in-class small molecule drug developed as a triple monoamine reuptake inhibitor, targeting the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). By inhibiting the reuptake of these neurotransmitters in the brain, tesofensine increases their synaptic concentrations, leading to appetite suppression and increased energy expenditure. Originally investigated for neurological disorders such as Parkinson’s disease and Alzheimer’s disease, its development shifted to obesity after significant weight loss was observed in clinical trials. Tesofensine has demonstrated robust anti-obesity effects in both animal models and human studies, with weight loss outcomes superior to many existing therapies. The drug is currently in Phase III clinical trials for obesity[1][2][3][4][5][6].

Other names

Tesofensine